VPC
IMA

Vestal Point Capital’s ImageneBio Inc IMA Stock Holding History

Vestal Point Capital’s Portfolio IMA Stock Details IMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-26,889
Closed -$636K – 65
2023
Q4 		$636K Buy
+26,889
New +$877K 0.07% 42

Other funds holding IMA

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vestal Point Capital's IMA Position: Q1 2024 in Review

Vestal Point Capital sold out of ImageneBio Inc (IMA) in Q1 2024, closing a stake of 26,889 shares — an estimated $636K sold.

Vestal Point Capital first reported a position in IMA in Q4 2023 and held it in 1 quarter. The position peaked at $636K in Q4 2023. 55 funds tracked by Wall St. Rank hold IMA as of Q1 2024.

  • Vestal Point Capital reported no remaining ImageneBio Inc position as of Q1 2024 after selling out during the quarter.
  • Vestal Point Capital sold 26,889 ImageneBio Inc shares in Q1 2024, an estimated $636K.
  • Vestal Point Capital first reported a position in ImageneBio Inc in Q4 2023 and held it in 1 quarter.
  • Vestal Point Capital's ImageneBio Inc position peaked at $636K in Q4 2023.
  • 55 funds tracked by Wall St. Rank held ImageneBio Inc as of Q1 2024.

Based on Vestal Point Capital's 13F filing for Q1 2024, filed 14 May 2024.